| Market Capitalization (Millions $) |
8 |
| Shares
Outstanding (Millions) |
0 |
| Employees |
3 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
64 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Galera Therapeutics Inc is a biotechnology company based in California, United States. The company focuses on developing and commercializing innovative therapeutics for the treatment of cancer and other diseases. Galera's main focus is on developing drugs that target the damaging effects of reactive oxygen species (ROS), which are produced in excess in cancer cells and other disease conditions.
The company's lead product candidate is known as GC4419, which is being developed as a treatment for the side effects of radiation therapy in cancer patients. Radiation therapy generates ROS, which can cause tissue damage and inflammation. GC4419 is designed to neutralize ROS and reduce the severity of side effects associated with radiation therapy, such as oral mucositis and radiation-induced fibrosis.
Galera Therapeutics is also exploring the potential of its technology in other therapeutic areas, including fibrosis and inflammation-related conditions. The company's approach involves using small molecules to target ROS and alleviate the damage caused by these molecules.
Overall, Galera Therapeutics aims to develop effective and safe therapies that improve the quality of life for patients with cancer and other diseases.
Company Address: 101 Lindenwood Drive, Suite 225 Malvern 19355 PA
Company Phone Number: 725-1500 Stock Exchange / Ticker: GRTX
|
%
